Zolbetuximab加化疗用于局部晚期不可切除或转移性胃癌或胃食管交界癌：通俗语言摘要

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials2026
2. 2Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials2024 · 25 citations
3. 3Safety and efficacy of zolbetuximab plus chemotherapy for CLDN18.2-positive gastric cancer: A single-center retrospective study.2026
4. 4Zolbetuximab: research progress and prospects in the treatment of gastric and gastroesophageal junction cancer targeting claudin 18.22026
5. 5Zolbetuximab: A Narrative Drug Review2026